Searched for
BIOLOGICS FACILITY ACQUISITION
No slowdown yet, but inflation and El Niño are risks: ITC's Sanjiv PuriITC Chairman Sanjiv Puri revealed plans for a Rs 20,000 crore investment over the medium term, including hotel expansion. He highlighted st...- Indian Army plans largest-ever K9 Vajra acquisition with order for 300 additional guns; check its featuresThe Indian Army plans to acquire 300 more K9 Vajra self-propelled guns. This significant order will boost the Regiment of Artillery. The K9...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Biocon Biologics gets global rights for biosimilar AdalimumabBiocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full control over ...
- Samsung Biologics to buy US drug production facility from GSK for $280 millionSamsung Biologics is acquiring its first U.S. drug production facility from GSK for $280 million to meet long-term U.S. market demand. The ...
- Zydus to acquire US biotech firm Agenus’ facilities in CaliforniaZydus Lifesciences is set to acquire Agenus Inc.'s biologics manufacturing facilities in California for $75 million upfront and $50 million...
- India's Syngene International acquires first US biologics facility for $36.5 millionIndia's Syngene International has agreed to acquire its first biologics facility in the U.S. from Emergent Manufacturing for $36.5 million....
- Biocon Biologics looks to trim $300 million debt in 1 yearBiocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in d...
- Biocon Biologics refinances 1.1 billion debt through US dollar bonds and new syndicated facilityThe bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security p...
- Eris Lifesciences acquires Biocon Biologics domestic branded formulation business for Rs 1,242 croreAs part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...
- Syngene Q2 Results: Net profit jumps 14% to Rs 117 croreNet profit before an exceptional item rose 20% YoY to 122 crore. The exceptional item pertains to transaction costs relating to the acquisi...
- Biocon Biologics appoints Shreehas Tambe as MD & CEOTambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...
- Biocon Biologics expects big gains from integration of Viatris business, SII dealBiocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...
- CCI clears Serum Institute Life Sciences-Biocon Biologics dealOnce the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...
- Biological E acquires Akorn India to ramp up vaccine & injectable medicine capacitiesAkorn India, a subsidiary of the US-based Akorn Inc., has a manufacturing plant of 39,000 square metres over a 14-acre campus in Himachal P...
- Biocon subsidiary acquires research facility from Pfizer HealthcareBiocon shares were trading 0.64 per cent higher that their previous close at Rs 226.85 on the BSE.
- Kemwell looks for buyouts in Baltic, taps PEs for new unitBangalore-based pharmaceutical company Kemwell is learnt to be in talks with private equity players for raising funds for a new biologic fa...
Load More
